Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06450184
Other study ID # PR/BE/23/296
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 11, 2024
Est. completion date March 9, 2024

Study information

Verified date June 2024
Source Humanis Saglik Anonim Sirketi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Pimavanserin 34 mg Capsule of Humanis Sağlık A.Ş., Turkey and NUPLAZID® (Pimavanserin) capsules of Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA in normal, healthy, adult, human subjects under fasting condition.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date March 9, 2024
Est. primary completion date January 17, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - A subject fulfilling the following criteria will be included in the present study: - Willing to provide written informed consent for participation in the study, and an ability to comprehend the nature and purpose of the study; - Willing to be available for the entire study period and to comply protocol requirements; - Normal, healthy, adult, human subject of 18-45 years (both inclusive) of age; - Body mass index in the range of 18.50 - 30.00 kg/m2 (both inclusive); - Normal health status as determined by baseline medical and medication history, at the time of screening and vital signs measurements and physical examination at the time of screening as well as check-in of each study period; - Normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests and urine analysis; - Normal or clinically non-significant 12-lead ECG recording; - Non-smokers; - Willing to abstain from chewing any tobacco containing products at least 72.00 hours prior to check-in until last sample collection in each study period; - Non-alcoholic; - Willing to abstain from xanthine or its derivative containing food or beverages (e.g. chocolates, tea, coffee or cola drinks), at least 48.00 hours prior to check-in until last sample collection in each study period; - Willing to abstain from grapefruit or its juice at least 72.00 hours prior to checkin until last sample collection in each study period; - For female subjects: - Negative urine pregnancy test during screening and negative serum ß-hCG test at the time of check-in of each study period; - Female subjects with child bearing potential or those within their first two years of onset of menopausal syndrome willing to either abstain from sexual intercourse, or should use of acceptable birth control methods for at least 15 days before 1st check-in till 15 days post last-dose / entire study period. [Acceptable birth control methods include barrier methods such as diaphragm/condom with or without spermicide or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed)]. Exclusion Criteria: - A subject with the following criteria will be excluded from the study: - Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract and of blood forming organs; - Significant history or current evidence of malignancy or chronic - infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, dermatological, immunological or psychiatric diseases, or organ dysfunction; - Any major illness or hospitalized within 90 days prior to the first check-in; - Requiring medication for any ailment having enzyme-modifying activity within one month prior to first check-in and throughout the study; - Use of any depot injection or an implant of any drug within 3 months prior to first check-in and throughout the study; - Use of any prescribed medication (including known to prolong QT interval, herbal medicines and vitamin supplements) or OTC products within 30 days prior to first check-in and throughout the study; - Presence of dementia related psychosis; - History or presence of significant gastric and/or duodenal ulceration; - Difficulty in swallowing tablets or capsules; - Use of any recreational drug or history of drug addiction; - Participated in any clinical investigation requiring repeated blood sampling or have donated blood in past 90 days prior to first check-in; - Positive urine alcohol and urine drug of abuse tests during check-in of each study period; - Reactive test for Human Immunodeficiency Virus (HIV) type I/II antibodies or Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibodies; - Lactating or nursing female subjects; - Female subjects using hormonal contraceptive (either oral/implants); - History of allergy or hypersensitivity intolerance to Pimavanserin or its formulation excipients which, in the opinion of a clinical investigator, would compromise the safety of the subject or the study; - History of difficulty in accessibility of veins in arms.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pimavanserin 34 mg
1 capsule of Pimavanserin Capsule 34mg
NUPLAZID 34 MG Oral Capsule
1 capsule of Pimavanserin Capsule 34mg

Locations

Country Name City State
India Raptim Research Pvt. Ltd., Navi Mumbai

Sponsors (1)

Lead Sponsor Collaborator
Humanis Saglik Anonim Sirketi

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum concentration obtained (Cmax) two-sided 90% CI for the test to reference ratio of the population means is within 80.00% to 125.00% for each of the Ln-transformed data Cmax 23 hours
Primary AUC from time 0 to last collection time 72 (AUC0-72) two-sided 90% CI for the test to reference ratio of the population means is within 80.00% to 125.00% for each of the Ln-transformed data AUC0-72 23 hours
Secondary Time of the maximum measured plasma concentration (Tmax) Description Statistics 23 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05824728 - Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis Phase 2
Terminated NCT03152292 - The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
Withdrawn NCT05344365 - A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis Phase 2
Recruiting NCT05357612 - Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases Phase 4
Completed NCT04292223 - Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis Phase 4
Completed NCT02969369 - A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis Phase 2
Not yet recruiting NCT05995782 - A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 Phase 1
Recruiting NCT04579887 - Presence Hallucination in Parkinson's Disease N/A
Recruiting NCT04592965 - Hallucinations in Parkinson's Disease N/A
Completed NCT05240339 - Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Recruiting NCT03661125 - SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis Early Phase 1